Literature DB >> 15640368

Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.

Yangjin Jegal1, Dong Soon Kim, Tae Sun Shim, Chae-Man Lim, Sang Do Lee, Younsuck Koh, Woo Sung Kim, Won Dong Kim, Jin Seong Lee, William D Travis, Masanori Kitaichi, Thomas V Colby.   

Abstract

The histopathologic pattern provides the most important prognostic marker for idiopathic interstitial pneumonia; however, studies have suggested that short-term changes in lung function may be more important. We investigated the prognostic factors for fibrotic interstitial pneumonia. The clinical features and follow-up course of 179 patients (131 with idiopathic pulmonary fibrosis and 48 with nonspecific interstitial pneumonia; 41 fibrotic types and 7 cellular) were analyzed retrospectively. The lung function indices improved or stabilized in most patients with fibrotic nonspecific interstitial pneumonia in contrast to the deterioration or stable condition of most patients with idiopathic pulmonary fibrosis. The 5-year survival of patients with fibrotic nonspecific interstitial pneumonia (76.2%) was better than for those with idiopathic pulmonary fibrosis (43.8%) (p = 0.007). Multivariate analysis at the time of presentation revealed that pathologic pattern, age, and diffusion capacity had important prognostic implications. However, after 6 months of follow-up, changes in FVC, initial diffusion capacity, and sex were the only independent prognostic factors, with no additional prognostic information conferred by the histologic diagnosis. Our data confirmed the importance of physiological parameters including short-term change in FVC. However, at the time of diagnosis, histopathology was important for the prediction of prognosis and future change in lung function.

Entities:  

Mesh:

Year:  2005        PMID: 15640368     DOI: 10.1164/rccm.200403-331OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  65 in total

1.  Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Ryo Yamazaki; Akiko Sano; Toshiyuki Yamagata; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
Journal:  Chron Respir Dis       Date:  2015-09-15       Impact factor: 2.444

2.  Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

3.  Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?

Authors:  Kevin R Flaherty; Adin-Cristian Andrei; Talmadge E King; Ganesh Raghu; Thomas V Colby; Athol Wells; Nadir Bassily; Kevin Brown; Roland du Bois; Andrew Flint; Steven E Gay; Barry H Gross; Ella A Kazerooni; Robert Knapp; Edmund Louvar; David Lynch; Andrew G Nicholson; John Quick; Victor J Thannickal; William D Travis; James Vyskocil; Frazer A Wadenstorer; Jeffrey Wilt; Galen B Toews; Susan Murray; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

4.  Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis.

Authors:  James W Voltz; Jeffrey W Card; Michelle A Carey; Laura M Degraff; Catherine D Ferguson; Gordon P Flake; James C Bonner; Kenneth S Korach; Darryl C Zeldin
Journal:  Am J Respir Cell Mol Biol       Date:  2008-02-14       Impact factor: 6.914

5.  Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia.

Authors:  Yukihiro Umeda; Yoshiki Demura; Takeshi Ishizaki; Shingo Ameshima; Isamu Miyamori; Yuji Saito; Tatsuro Tsuchida; Yasuhisa Fujibayashi; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-27       Impact factor: 9.236

6.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

7.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Lyrica Xiaohong Liu; Caroline Motika; Ella A Kazerooni; Barry H Gross; William D Travis; Thomas V Colby; Susan Murray; Galen B Toews; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

8.  Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Authors:  Sean J Callahan; Meng Xia; Susan Murray; Kevin R Flaherty
Journal:  Respir Med       Date:  2016-08-31       Impact factor: 3.415

9.  Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Fernando J Martinez; Lyrica X Liu; Susan Murray; Meilan K Han; Ella A Kazerooni; Barry H Gross; Jeffrey Myers; William D Travis; Thomas V Colby; Galen B Toews; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2010-01-07       Impact factor: 21.405

10.  Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function.

Authors:  Sung-Woo Park; Mi-Hyun Ahn; Hee Kyung Jang; An Soo Jang; Do-Jin Kim; Eun-Suk Koh; Jong-Sook Park; Soo-Taek Uh; Yong Hoon Kim; Jai Soung Park; Sang Hyun Paik; Hwa-Kyun Shin; Wook Youm; Choon-Sik Park
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.